Mydecine Innovations Group Announces Results Of Shareholder Meeting And Provides Corporate Update

Core Points - Mydecine Innovations Group Inc. announced the results of its annual general and special meeting of shareholders held on October 1, 2025, where all resolutions were approved [1][2] Debt Settlements with Related Parties - Disinterested shareholders approved the settlement of debts totaling USD $1,386,391 owed to two insiders through the issuance of convertible debentures amounting to USD $100,000 [3] - A debt settlement agreement with CEO Josh Bartch was approved to settle CAD $1,309,836 of unpaid management fees, with a convertible debenture issued for the same amount [4] - The company settled CAD $7,878,792 owed to Pioneer Garage Limited through a convertible debenture with the same terms as the Bartch agreement [5] - The Settlement Debentures will not accrue interest prior to an event of default, with an interest rate of 8% per annum upon default [6] Debt Settlement with an Arm's Length Party - A debt settlement agreement was made with an arm's length creditor to settle CAD $243,479 of legal fees through a secured convertible debenture of USD $100,000, bearing 1% monthly interest [9][10] Share Consolidation - Shareholders approved a special resolution allowing the Board to consolidate the company's issued and outstanding common shares on a basis of up to one post-consolidation share for every 50 pre-consolidation shares [13]